Pharmacokinetics of grepafloxacin

Area of Science:

• Pharmacology
• Microbiology
• Drug Development

Background:

• Grepafloxacin is a novel fluoroquinolone antibiotic.
• Understanding its pharmacokinetic profile is crucial for therapeutic efficacy.

Purpose of the Study:

• To characterize the pharmacokinetic properties of grepafloxacin in healthy volunteers.
• To evaluate the influence of various factors on grepafloxacin pharmacokinetics.
• To assess grepafloxacin tissue distribution and potential clinical applications.

Main Methods:

• Oral administration of grepafloxacin to healthy volunteers.
• Plasma concentration monitoring over time.
• Analysis of absorption, distribution, metabolism, and excretion (ADME) parameters.
• Evaluation of effects of food, gastric pH, gender, age, and organ impairment.

Main Results:

• Rapid oral absorption with peak plasma levels at 2 hours and a 12-hour half-life.
• Elimination primarily via metabolism and fecal excretion; renal clearance is minimal (10-15%).
• Dose-dependent increases in plasma concentrations observed, but not clinically significant within therapeutic ranges. Absorption unaffected by food or gastric pH.
• Hepatic impairment increases plasma concentrations and AUC; renal impairment has no effect.
• Higher concentrations achieved in lung, genital, bile, and gallbladder tissues compared to serum.
• Accumulation in polymorphonuclear leukocytes observed.

Conclusions:

• Grepafloxacin exhibits favorable pharmacokinetic properties for oral administration.
• Its distribution into various tissues suggests potential for treating respiratory and sexually transmitted infections.
• Hepatic impairment necessitates careful consideration, while renal impairment does not significantly alter pharmacokinetics.
• Potential utility against intracellular pathogens due to accumulation in leukocytes.